David Kaufman, who joined San Francisco-based Third Rock Ventures in 2020 and was promoted to partner at the company in 2022, has a varied resume outside of venture capital investing. He was previously chief medical officer and head of translational development at the Bill and Melinda Gates Medical Research Institute, and before that held several R&D roles at Merck & Co.
From Big Pharma To VC: The Road Travelled By Third Rock’s David Kaufman
VC Playbook: Partner at Third Rock Ventures, David Kaufman, talks to In Vivo about the venture capital firm’s company creation strategy and seeking ‘white space’ in biopharma for innovation.
More from C-Suite Speaks
• By
Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.
• By
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
• By
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.
• By
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
More from Leadership
• By
Top 30 leaders: see the list of industry influencers highlighted in the sixth edition of In Vivo's Rising Leaders series.
• By
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.
• By
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.